Korean Journal of Pharmacognosy (생약학회지)

The Korean Society of Pharmacognosy (한국생약학회)
권호 표지

Inhibitory potency of Acetylcholinesterase and Amyloid beta(1-42) peptide aggregation to the Extracts of Enthusiasm Reducing herbals

청열약 추출물들의 아세틸콜린에스테라제 저해와 베타아밀로이드 펩티드 응집 억제 효능

  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Inhibition of acetylcholinesterase and amyloid beta(1-42) peptide is good drug targets for Alzheimer's disease therapeutics. Among the twenty enthusiasm reducing herbals, the 70% methanol extracts (1 mg/ml) of Moutan Radicis Cortex and Forsythiae Fructus showed 91.5% and 85.3% about acethylcholinesterase inhibition, respectively. The extracts (1 mg/ml) of Coptidis Rhizoma and Paeoniae Radix Rubra showed more than 85% inhibition rate against amyloid beta (1-42) peptide aggregation. The neuroprotective effect of the extracts (1 mg/ml) of Moutan Radicis Cortex, Forsythiae Fructus and Paeoniae Radix Rubra showed 90.0%, 87.4% and 85.1% to compare with amyloid beta (1-42) peptide treated cells (IMR-32), respectively. Three herbs, Moutan Radicis Cortex, Forsythiae Fructus and Paeoniae Radix Rubra are promising candidates from natural products for development of Alzheimer's disease therapeutics.

Keywords

References

  1. Khachaturian Z.S. (1985) Diagnosis of Alzhemier's Disease. Arch. Neurol. 42, 1097 https://doi.org/10.1001/archneur.1985.04060100083029
  2. Selkoe D.J. (1999) Translating Cell Biology into Therapeutic Advances in Alzhemier's Disease. Nature, 399, A23-A31 https://doi.org/10.1038/19866
  3. Hollander E, Mohs R.C., Davis K.L. (1986) Cholinergic Approaches to the Treatment of Alzheimer's Disease. Br. Med. Bull. 142, 97
  4. Pietrzik C., Behl C. (2005) Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173 https://doi.org/10.1111/j.0959-9673.2005.00435.x
  5. Silverberg G.D., Mayo M., Saul T., Carvalho J., McGuire D. (2004) Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97 https://doi.org/10.1586/14737175.4.1.97
  6. Cottingham M.G., Voskuil J.L., Vaux D.J. (2003) The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry, 42, 10863 https://doi.org/10.1021/bi034768i
  7. Prous J., Rabasseda X., Castaner J. (1996) SDZ-ENA-713 Cognition Enhancer Acetylcholinesterase Inhibitor. Drugs Future, 19, 656
  8. Lilienfeld S. (2002) Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159 https://doi.org/10.1111/j.1527-3458.2002.tb00221.x
  9. Cottingham M.G., Hollinshead M.S., Vaux D.J. (2002) Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry, 41, 13539 https://doi.org/10.1021/bi0260334
  10. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. (2001) A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 40, 10447 https://doi.org/10.1021/bi0101392
  11. Kurz A. (1998) The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295
  12. Sugimoto H. (2001) Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63 https://doi.org/10.1002/1528-0691(2001)1:1<63::AID-TCR9>3.0.CO;2-J
  13. Jann M.W. (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 20, 1 https://doi.org/10.1592/phco.20.1.1.34664
  14. Zarotsky V., Sramek J.J., Cutler N.R. (2003) Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446
  15. Barril X., Orozco M., Luque F.J. (2001) Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255 https://doi.org/10.2174/1389557013406828
  16. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. (2003) Alzheimer's disease- affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA. 100, 10417
  17. 본초학 (2004) 영림사, 편집부, 777p
  18. 생약학 (2006) 동명사, 생약학교재편찬위원회, 523p, 420p